(Reuters) – The U.S. Food and Drug Administration on Saturday approved a standalone at-home sample collection kit for COVID-19 diagnostic testing.
The regulator has given an emergency use authorization (EUA) to Everlywell Inc, a health and wellness company, for its COVID-19 test home collection kit.
Everlywell launched the COVID-19 at-home collection kit last month.
Reporting by Maria Ponnezhath in Bengaluru; Editing by Matthew Lewis
View original article here Source